Richard E. Pratley MD
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute, Orlando, Florida; Medical Director, AdventHealth Diabetes Institute, Orlando, Florida; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MarylandDr. Richard Pratley, an internationally recognized expert in diabetes, is Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute and Medical Director of the AdventHealth Diabetes Institute in Orlando, as well as Adjunct Professor of Medicine, Johns Hopkins University School of Medicine.
Dr. Pratley is a principal investigator for both NIH- and pharmaceutical company–sponsored trials in diabetes and obesity. His current research interests include the prevention of diabetes, improving the care of older individuals with diabetes, developing new drugs to treat and prevent diabetes and its complications, understanding the role of the fat cell in increasing the risk for diabetes and heart disease, and investigating extracellular vesicles in inter-cellular and inter-organ cross-talk. He presents his research regularly at national and international meetings and has written over 300 peer-reviewed articles. He is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has served on the editorial boards of a number of high impact journals, including Diabetes Care, The Lancet Diabetes and Endocrinology, The Journal of Clinical Endocrinology & Metabolism, and the Journal of Diabetes and Its Complications.
After receiving his medical degree from Wayne State University in Detroit and undergoing residency training in internal medicine the University of Michigan in Ann Arbor, he completed fellowships in geriatric medicine and gerontology at the University of Michigan, Johns Hopkins University, and the National Institute on Aging.
Positions:
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Medical Director, AdventHealth Diabetes Institute; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
Degrees:
MD: Wayne State University, Detroit, Michigan
Postgraduate Training:
Fellowship (geriatric medicine and gerontology): University of Michigan, Johns Hopkins University, National Institute on Aging
Research Interests:
Prevention of diabetes; improving the care of older individuals with diabetes; developing new drugs to treat and prevent diabetes and its complications; understanding the role of the fat cell in increasing the risk for diabetes and heart disease; investigating extracellular vesicles in inter-cellular and inter-organ cross-talk.
Disclosures
Dr. Pratley has received the following (directed to his institution): speaker fees from Merck and Novo Nordisk; consulting fees from Bayer AG, Endogenex, Inc., Gasherbrum Bio, Inc., Hengrui (USA) Ltd., Intas Pharmaceuticals, Inc., Lilly, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., and Sun Pharmaceutical Industries; and grants from Dompe and Novo Nordisk.
Recent Contributions to PracticeUpdate:
- Oral Semaglutide vs Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin
- Oral Semaglutide Is Safe and Effective Added to Insulin ± Metformin in Patients With T2D
- The Association Between Polypharmacy and Adverse Health Consequences in Elderly Patients With Type 2 Diabetes
- Efficacy and Safety of Oral Semaglutide With Flexible Dose Adjustment vs Sitagliptin in Type 2 Diabetes
- DPP-4 Inhibitors and Risk of IBD Among Patients With Type 2 Diabetes
- ADA Scientific Sessions 2019: Recommendations From Dr. Richard Pratley
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- 2018 Top Stories in Diabetes: The ASCEND Study
- Type 2 Diabetes and Fatty Liver/Non-alcoholic Steatohepatitis
- Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily in Type 2 Diabetes